Dr. Drew Moghanaki has been recognized as a fellow by the American Society for Radiation Oncology
Dr. Drew Moghanaki, a renowned figure in the field of radiation oncology, has been named a 2025 fellow of the American Society for Radiation Oncology (ASTRO). This prestigious recognition is awarded annually to individuals for exceptional achievements in radiation therapy.
The ASTRO Annual Meeting, scheduled to take place in San Francisco on Tuesday, September 30, will see Dr. Moghanaki honoured for his contributions to the advancement of radiation therapy. His work, which is dedicated to advancing radiation therapy and developing innovative treatment options for people diagnosed with lung cancer and other challenging cancers, has been highlighted for its critical role in cancer treatment.
Dr. Moghanaki's work focuses specifically on people diagnosed with lung cancer. He is currently conducting research at the Jonsson Comprehensive Cancer Center and UCLA's Department of Radiation Oncology, where he is working on improving radiation therapy techniques and outcomes for lung cancer patients. One of his research efforts is the national VALOR clinical trial, where he is comparing outcomes for patients treated with SBRT versus surgery.
Through the VALOR clinical trial, Dr. Moghanaki is providing critical evidence on non-invasive alternatives to traditional lung surgery. He is renowned for his expertise in high-precision, non-invasive radiation therapies such as stereotactic body radiation therapy (SBRT), intensity-modulated radiation therapy (IMRT), and magnetic resonance-guided radiation therapy (MRgRT).
In addition to his work with lung cancer, Dr. Moghanaki's work also extends to developing innovative treatment options for people diagnosed with other challenging cancers. His work in this area is a testament to his commitment to improving the lives of cancer patients through advanced radiation therapy techniques.
Dr. Moghanaki joins many outstanding physicians and scientists in the 2025 class of ASTRO fellows. His recognition as an ASTRO fellow is for exceptional achievements in radiation therapy, and it is a well-deserved honour for his dedication to advancing radiation therapy and providing better treatment options for cancer patients.
